It is a bad time for biotechnology firms. Since the start of 2002, biotech stocks have gone down and as a consequence, biotech funds have dipped too. The American Stock Exchange Biotechnology Index is being recorded at 415.90 points. It was at a high of 657.67 points last June. The latest casualty of this slump is Icos Corporation, which is developing a drug to compete with Viagra. The Food and Drug Administration has said that the drug, called Cialis, is approvable but needs more review. Delay in introducing Cialis has hit Eli Lilly & Co too, which will market the drug. Last December, the federal drug agency had declined to even consider the proposed cancer drug manufactured by ImoClone System Incorporate. Biofirms blame it on the agency which they say has become conservative about safety standard.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.